ABSTRACT -Purpose. We investigated whether the recent implementation of the regulatory requirements
INTRODUCTION
The well-acknowledged sub-standard quality of natural products in terms of their active ingredient content is generally attributed to the lack of regulations in their production and marketing (1) (2) (3) . In 2002 we reported that 12 out of 13 Canadian products of glucosamine had substantially less active ingredient than what was stated on their respective labels (1) . This has been suggested to be, at least in part, responsible for the controversy in the effectiveness of glucosamine as an anti-inflammatory drug (2) . This is important, not only in terms of the product standard and regulatory issues but also therapeutically as recent data suggest dose/plasma concentration-dependence for the beneficial effects of glucosamine (4) . Only in a few regions, e.g., the European Union, but not in North America, is glucosamine regulated as a pharmaceutical product. Recently, Health Canada has implemented a set of regulatory guidances governing natural products (5). Our aim was to examine if the introduction of these guidances has resulted in an improvement of the quality of Canadian glucosamine products. Since, most solid dosage forms of glucosamine contain sodium or potassium chloride for their physical stability, we also determined their potassium and sodium contents to assess if they exceeded the recommended safety limits.
MATERIAL AND METHODS
Glucosamine HCl, mannosamine HCl, amantadine HCl (1-aminoadmantane HCl, ADAM) and 9-fluorenylmethoxycarbonyl chloride (FMOC-CL) were purchased from Sigma-Aldrich Canada, LTD, (Oakville, ON, Canada), high performance liquid chromatography (HPLC) grade acetonitrile and water were obtained from Caledon Laboratories Ltd, (ON, Canada).
Products
We searched the market for available glucosamine products, particularly those that we had examined and reported on in 2002 (1). We succeeded in purchasing 11 products (Table 1 ) from pharmacies or health products stores with 8 of them being those examined previously.
Sample preparation and glucosamine assay
Glucosamine stock solution was prepared by dissolving 60 mg glucosamine HCl in 100 mL water to yield a 0.5 mg/mL solution of glucosamine base.
The stock solution was further diluted with water to give standard solutions containing 0.78, 1.56, 3.12, 6.25, and 12.5 µg/mL, respectively.
The worker was kept blinded to the identity of the products. A positive control (Rottapharm, Monza, Italy) and a placebo tablet were also tested. Tablets and capsules were tested for their glucosamine and electrolytes contents. Five units of each tablet product were weighed, placed in a mortar and ground to a fine powder. For capsules the entire contents of 5 units were used. Four portions each of approximately 10% of the total powder were accurately weighed. Three portions were used for glucosamine determination and one for the electrolytes measurement. For glucosamine assay, the powders were dissolved in 1 L of distilled water by vortex-mixing for 30 min and passed through paper filter. Glucosamine salts are highly soluble in water, hence, it was expected to be all in the clear solutions. For the liquid formulations, 2 mL of the products were used. The solutions were diluted with water to yield a concentration of 10 mg/L and assayed for glucosamine using HPLC according to a previously reported procedure (6) . Briefly, a 0.1 mL aliquot of standard or sample solution was spiked with 50 μL of 10 μg/mL internal standard (mannosamine HCl) and 50 μL of borate buffer (pH 8.5) added followed by addition of 50 μL of a freshly prepared FMOC-CL solution. This was followed by 1 min vortex-mixing and incubation in a water bath at 30° C for 30 min. Subsequently, 50 μL of ADAM 50 mg/mL in acetonitrile:water (1:1) was added to the test tubes to react with the excess derivatizing agent. The samples were then diluted with 1 mL acetonitrile:water (1:1) and 5 μL injected into the HPLC. The inter-day / intra-day assay coefficient of variation of the assay and the percent error were both less than 10%. All products were tested within their manufacturer's recommended expiry dates.
Potassium and sodium assays
Instrumental neutron activation analysis (INAA) was used to determine the potassium and sodium contents of the products under study. Powdered samples, each measuring 200 mg, were accurately weighed into 300 µL polyethylene micro-centrifuge tubes, hermetically sealed, and irradiated consecutively in 2 Co) housed in a 10 cm Pb cave. The Ge detector was connected to an ORTEC DSPEC Pro digital spectrometer and measurements were performed in zero dead time counting mode. Elemental determinations were performed by the semi-absolute method of neutron activation analysis (7). K was determined via the 1524.7 keV gamma-ray emission of Table 1 ; b Data presented as mean (SD), n=3/product; c 1500 mg is the common daily dose. ND, not determined.
using the 1368.6 keV gamma-ray emission of 24 Na (T½, 15.0 h) produced via the neutron reaction 23 Na(n,) 24 Na. The K and Na comparator standards were prepared from Aldrich Chemical Co., gold label potassium-and sodium-carbonate, both of 99.999% purity, that had been dried for over 3 hours at 105 ± 5 °C. Sodium was quantified in all the samples analyzed. However, the European product contained a high level of sodium and no detectable level of potassium. For that sample the K detection limit was calculated following Currie (8) .
RESULTS AND DISCUSSION
The pharmaceutical grade product available in the European market contained 94%±1.1 of the label claim amount of glucosamine which was within the acceptable range (Table 2) . No glucosamine was detected in the placebo.
Since 2012 all natural health products must be licensed before they can be sold in Canada. To become licensed, applicants must provide Health Canada detailed information on the product, including its medicinal ingredients, source, dose, potency, non-medicinal ingredients and recommended use(s) (5).
As depicted in Tables 1 and 2 , we were able to acquire 8 products whose glucosamine content had been previously reported (1) . In addition, we tested two liquid formulations and one capsule as well as a European pharmaceutical grade product that had not been included in our 2002 report. Overall, the glucosamine content of the tested products ranged from 71 to 110% of their respective label claim. Eight of the 11 tested Canadian products contained more than 91% of what was claimed on the label. The three new Canadian products contained 101-110% of the label claim.
According to the USP a typical pharmaceutical formulation should contain from 90 to 110% of the labeled amount (9). Glucosamine is not considered as a pharmaceutical product in Canada and the USA. However, it is listed in the USP and its tablets or capsules are expected to contain 90-110% of claimed amount (9). The Health Canada regulatory requirement states that "The tolerance limits for the quantity of medicinal ingredients should conform to the relevant pharmacopoeial standard or in its absence to 80% to 120% of the label amount" (5). Assuming the USP as a "relevant pharmacopoeia", glucosamine products should contain 90-110% of the label claim. Accordingly, 9 of the 11 tested products contain acceptable pharmaceutical potencies. In contrast, in 2002, 7 of the 8 of the tested products were found to contain only 42-65% of the label claim (1).
The substantial improvement in the quality of the examined products is encouraging. It is, however, unclear whether the observed improvement is due to the implementation of the regulations (5) or the awareness that was brought about through the literature (1-3).
It is, however, still alarming that two of the previously tested products that had 42 and 55% of the label claim, albeit improved, have lower than the acceptable 90% limit (78 and 71%, respectively). The sub-standard quality of the products observed in this study, although just a few, may be attributed to the soft nature of the regulatory requirements and/or the lack of an obligation to conform for already marketed products. The Health Canada Guidance states that "Because Health Canada has not yet evaluated all natural health products currently on the market, products with exemption numbers can also legally be sold in Canada. The exemption number will be listed on the product label in the form EN-XXXXXX" (5)". We found only the natural health number (NPN) on all of the Canadian products ( Table 1 ).
The observed sub-standard quality appears to be not limited to the available natural products. They collected 125 active pharmaceutical ingredients used for compounding and 73 finished formulations prepared onsite. The samples comprised female hormone, inhalation and local anesthetic products. For various reasons only 36 samples were analyzed for their potency. Nevertheless, 12 of the 36 samples, i.e., 33% failed to meet the required criteria set by the agency due to both sub-or super-potencies ranging from as low as 67.5% to as high an 268% of the labeled claim. To the best of our knowledge, such data are not available for products compounded in other countries but it is reasonable to predict similar conditions to those reported in the USA. Similar to the natural products, on-site compounded formulations are subject to very few, if any, regulations. Hence, the quality of both natural products and pharmacy compounded formulations is likely more dependent on the skills and standards of the makers rather than the regulatory guidelines.
The observation that the tested liquid formulations contain glucosamine at the pharmaceutical grade level is therapeutically important. Glucosamine tablets are excessively bulky -up to 2.3 g/tablet (Table 1) -, making them difficult to swallow, particularly so by elderly subjects that constitute a large portion of patients in need of the compound. The large size of the products contributes, at least in part, to the suggestion of underdosing of glucosamine (2) . Glucosamine salts are highly water soluble, hence, their liquid formulations can readily be prepared. The availability of these readily swallowable liquid formulations may improve patient compliance.
Depending on the information source, the daily requirement of sodium ranges from 1.3 to 1.5 g (11). In general, the average North American adult consumes much more that than the required sodium amount. For potassium the daily requirement is approximately 4.5-4.7 g (9). The sodium and potassium contents of the tested products, adjusted for the common daily dosage of 1500 mg/kg, was very variable for both sodium (0.05-104.3 mg) and potassium ( 17.9-361.7 mg) but were not at levels to raise concern.
In conclusion, there is a substantial improvement in the quality of the present glucosamine products available in Canada as compared to those tested in 2002. This, although cannot be unequivocally claimed, may be attributed to the implementation of the new regulatory requirements governing natural products. Nevertheless, one can still find substandard products due, perhaps, to the less stringent nature of the regulations governing natural products as compared with those in place for pharmaceutical products and the overwhelming availability of the products introduced to the market before the new guidance.
